New hope for painful, scarring scalp disease that defies antibiotics
NCT ID NCT07268534
Summary
This study is testing three different biologic drugs (adalimumab, ustekinumab, and baricitinib) to see if they can control painful flare-ups of folliculitis decalvans, a rare condition that causes scarring hair loss. It is for adults whose disease has not been controlled by at least two rounds of standard antibiotic treatments. The main goal is to see if these drugs, which target the body's immune system, can reduce disease activity over 6 months compared to a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULITIS DECALVANS (FD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.